Literature DB >> 10992483

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

A Bacon1, J Makin, P J Sizer, I Jabbal-Gill, M Hinchcliffe, L Illum, S Chatfield, M Roberts.   

Abstract

We have evaluated the ability of two carbohydrate biopolymers, chitosan and gellan, to enhance antibody responses to subunit influenza virus vaccines delivered to the respiratory tracts of mice. Groups of mice were vaccinated three times intranasally (i.n.) with 10 microg of purified influenza B/Panama virus surface antigens (PSAs), which consist of hemagglutinin (HA) and neuraminidase (NA), either alone or admixed with chitosan or gellan solutions. Separate groups were vaccinated subcutaneously (s.c.) with PSAs adsorbed to Alhydrogel or chitosan or gellan alone i.n. Serum antibody responses were determined by enzyme-linked immunosorbent assay (ELISA) for influenza virus-specific immunoglobulin G (IgG) and by HA inhibition (HAI) and NA inhibition (NAI) assays. The local respiratory immune response was measured by assaying for influenza virus-specific IgA antibody in nasal secretions and by enumerating nasal and pulmonary lymphocytes secreting IgA, IgG, and IgM anti-influenza virus-specific antibodies by enzyme-linked immunospotting (ELISPOT). When administered alone i.n., B/Panama PSA was poorly immunogenic. Parenteral immunization with B/Panama PSA with Alhydrogel elicited high titers of anti-B/Panama antibodies in serum but a very poor respiratory anti-B/Panama IgA response. In contrast, i.n. immunization with PSA plus chitosan stimulated very strong local and systemic anti-B/Panama responses. Gellan also enhanced the local and serum antibody responses to i.n. PSA but not to the same extent as chitosan. The ability of chitosan to augment the immunogenicity of influenza vaccines given i.n. was confirmed using PSA prepared from an influenza A virus (A/Texas H1N1).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992483      PMCID: PMC101535          DOI: 10.1128/IAI.68.10.5764-5770.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  CpG motifs as immune adjuvants.

Authors:  D M Klinman; K M Barnhart; J Conover
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

2.  Effect of chitosan on epithelial permeability and structure.

Authors:  V Dodane; M Amin Khan; J R Merwin
Journal:  Int J Pharm       Date:  1999-05-10       Impact factor: 5.875

3.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

4.  Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers.

Authors:  T J Aspden; J D Mason; N S Jones; J Lowe; O Skaugrud; L Illum
Journal:  J Pharm Sci       Date:  1997-04       Impact factor: 3.534

5.  Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions.

Authors:  J C Hierholzer; M T Suggs
Journal:  Appl Microbiol       Date:  1969-11

6.  Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.

Authors:  I Jabbal-Gill; A N Fisher; R Rappuoli; S S Davis; L Illum
Journal:  Vaccine       Date:  1998-12       Impact factor: 3.641

7.  A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10

8.  Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.

Authors:  J D Barackman; G Ott; D T O'Hagan
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

9.  The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.

Authors:  G L Barchfeld; A L Hessler; M Chen; M Pizza; R Rappuoli; G A Van Nest
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

Review 10.  Mucosal immunity and tolerance: relevance to vaccine development.

Authors:  C Czerkinsky; F Anjuere; J R McGhee; A George-Chandy; J Holmgren; M P Kieny; K Fujiyashi; J F Mestecky; V Pierrefite-Carle; C Rask; J B Sun
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

View more
  21 in total

1.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 2.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.

Authors:  Zhiming Huo; Ruchi Sinha; Edel A McNeela; Ray Borrow; Rafaela Giemza; Catherine Cosgrove; Paul T Heath; Kingston H G Mills; Rino Rappuoli; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route.

Authors:  Andrew L Lewis; Faron Jordan; Lisbeth Illum
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

5.  Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics.

Authors:  Udhumansha Ubaidulla; Molugu V S Reddy; Kumaresan Ruckmani; Farhan J Ahmad; Roop K Khar
Journal:  AAPS PharmSciTech       Date:  2007-01-19       Impact factor: 3.246

Review 6.  Towards antiviral polymer composites to combat COVID-19 transmission.

Authors:  Adrian P Mouritz; Joel Galos; Denver P Linklater; Raj B Ladani; Everson Kandare; Russell J Crawford; Elena P Ivanova
Journal:  Nano Sel       Date:  2021-05-04

7.  Chitosan can stop or postpone the death of the suckling mice challenged with foot-and-mouth disease virus.

Authors:  Dong Li
Journal:  Virol J       Date:  2010-06-12       Impact factor: 4.099

8.  Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.

Authors:  Mariko Ishii; Naoya Kojima
Journal:  Glycoconj J       Date:  2009-10-09       Impact factor: 2.916

9.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

10.  The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder.

Authors:  Mohsen Tafaghodi; Maryam Eskandari
Journal:  Iran J Basic Med Sci       Date:  2012-05       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.